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Elizabeth A. Clark, Shaban Khaled, Richard J. M. Hague, Christopher J. Tuck,
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and Ricky D. Wildman*
A strategy for creating tuneable 3D printed drug delivery devices is proposed.
3D printing offers the opportunity for improved compliance and patient
treatment outcomes through personalization, but bottlenecks include finding
formulations that provide a choice of drug loading and release rate, that are
tuneable, and avoid the need for surgical removal. The suggested solution is
to exploit 3D inkjet printing freedoms. A reactive prodrug is used that can
polymerize into drug-attached macromolecules during 3D printing and by
tuning the hydrophilicity, hydrolysis can be facilitated or hindered, which in
turn controls drug release. To demonstrate this approach, ibuprofen is
attached to 2-hydroxyethyl acrylate through a cleavable ester bond, formulated
for inkjet 3D printing, and then printed to produce a solid dosage form. This
allows a much higher loading than is usually achievable—in this case up to
58 wt%. Of equal importance, the 3D inkjet printing freedoms mean that the
drug delivery device is highly tuneable: by selection of spacer monomers to
adjust the hydrophilicity; through geometry; by spatially varying the
components. Consequently, hierarchical release systems are created bespoke,
from the molecular to macro. This approach represents a new paradigm for
the formulation of printable inks for drug-loaded medical devices.
1. Introduction
We propose a prodrug-based strategy to challenges associ-
ated with the formulation of multi-material Inkjet-based 3D
Printing (IJ3DP) inks for personalized medicine applications.
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There are a number of barriers to the cre-
ation of personalized viable implants capa-
ble of long-term drug release. These include
requirements for sustained drug loading
with controlled degradation/release, degra-
dation to nontoxic products, and to be
cost effective and industrially scalable.[1–3]
3D printing offers promising routes to
overcome these, and also offers ways
to include significant additional benefits
through: first, being able to selectively com-
bine multiple drugs into a single system
to help address poor compliance associated
with high medication burden, and second,
facile personalization through on-demand
fabrication.[3–7] 3D printing methods have
been successfully exploited for pharmaceu-
tical delivery using techniques as diverse as
extrusion,[8–12] stereolithography,[13–15] and
binder jetting.[16–18] This latter method is
particularly exciting since it has high scal-
ability and has indeed already been used
for a commercial product (Aprecia). IJ3DP
offers a combination of benefits, placing it within the portfo-
lio of 3D printing techniques that are available for fabricating
solid dosage forms and implants. IJ3DP strengths come into
play when there is a need for industrial scalability, high reso-
lution, and multi-material manufacture all to be present.[19–21]
Its suitability for the production of tablets has already been
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demonstrated in the works of Acosta-Vélez et al.,[22] Kyobula
et al.,[4] and Clark et al.,[23] who each developed adaptations of ink
jet printing for drug release over the order of a few hours. Extend-
ing this to release over several months as required for an implant
is a challenge that requires innovation in both process and ma-
terials. This is because in order to achieve an effective dose over
a sustained period, whilst keeping the implant to a size where
we can implant with a cannula, we need a high drug loading, and
this is not easy without drug precipitation and increases in viscos-
ity that prevent inkjet printing. Consequently, we need to create
new safe materials, and combine them into functional formu-
lations that can host high drug loadings, sustained degrade, and
elute over months whilst still retain the ability to process through
IJ3DP.
To overcome these issues, we offer a reactive prodrug-based
formulation concept not previously used for IJ3DP. There have
been a number of studies on attaching a target drug molecule to
functional carriers, through temporary decomposable bonds to
achieve controlled or targeted release behavior.[24–29] To the best
of our knowledge, however, there has not been any attempt to
apply such a concept in formulating for IJ3DP to solve its print-
ability challenges and produce controlled-release structures. This
approach allows us to design from the molecular scale to give
high drug loadings, while retaining the ability to print. Our for-
mulation can be tailored to achieve a range of release profiles
through changing the molecular structure, the composition of
the formulation, by printing with multiple materials, or through
manipulating the geometry. We demonstrate the design of a re-
active prodrug using a low viscosity reactive linker which con-
tains two side groups (Figure 1a); one of which can form a tem-
porary bond with the target drug molecules, while the other side
group is able to polymerize to form solid structures during the
IJ3DP process. Formulations based on a reactive prodrug strat-
egy can obtain control over the drug release since the precise
design of the polymerized molecular structure determines the
rate at which the bonds that link the drug to the reactive prodrug
linker are broken. Throughmethodical selection of the linker, ad-
ditives, and printed geometry, this approach can enable hierarchi-
cal personalization of the drug release behavior at the synthesis,
formulation, and printing stages.
This concept has been tested via an ester-bonded pro-
drug model for ibuprofen (Figure 1b). The ester bond has
been reported to have accelerated decomposition in alkaline
environments.[28,29] Previous studies have also demonstrated that
drugs grafted to the molecules via ester bonds can detach and
release through a hydrolysis reaction.[30–32] Such a concept, how-
ever, can also be extended to other kinds of temporary bond-
ing systems, for example, the acetyl bond, which has acceler-
ated decomposition in an acidic environment.[33–35] In our study,
the carboxylic acid functionality of ibuprofen and the hydroxyl
group of the reactive linker have been induced to undergo an
esterification reaction to produce an ester-bonded photo-curable
drugmolecule. 2-hydroxyethyl acrylate, 2-hydroxyethylmethacry-
late, and 2-hydroxyethyl acrylamide were selected as reactive
linker candidates, which contain both hydroxyl groups and pho-
topolymerizable groups. This approach would hence be directly
applicable to the very many drugs that have a carboxylic acid
functionality,[36] and as stated, can readily be adapted to other
chemical moieties.
Our approach has a number of elements that provide advan-
tages over commonly used formulating strategies: First, we are
able to achieve ink formulations that can hold up 58 w/w% drug
loading and are amenable to IJ3DP processing; second, through
the tuning of the ink formulation we have also demonstrated
that manipulation of the release profile of the printed product
is possible; third, as the drug is released, the polymer backbone
structure dissolves avoiding the necessity for surgical removal.
Finally, the ability to use IJ3DP offers a macroscopic control over
release and personalization, since it enables the bespoke fabri-
cation of complex geometries to meet the need of individuals,
while the multi-material facet of IJ3DP allows for tailoring of the
material spatial distribution at the voxel level. Our approach will,
Figure 1. Schematic of the approach used to prepare a reactive prodrug for ink formulation development. a) The selected drug candidate was grafted
to a reactive monomer by a degradable covalent bond and prepared into inkjet printable formulations by mixing with additives that can tune the release
speed;[37,38] The developed formulation was inkjet-printed and polymerized in situ by UV photo-polymerization to form a solid 3D structure; b) Molecular
structures of ibuprofen, hydroxyethyl acrylate, and synthesized reactive prodrug; c) Bespoke tablets with a spatially varying drug distribution fabricated
with multi-material IJ3DP.
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therefore, potentially enable the “programming” of the drug de-
livery device’s active pharmaceutical ingredient distribution and
hence its release profile through a number of levers. Figure 1c is
an image of a showcase tablet structure printed with IJ3DP.
2. Results and Discussion
Our general approach was to combine ibuprofen attached reac-
tive prodrugs with reactive diluents at various ratios (Table S1,
Supporting Information), in order to obtain a range of formula-
tions with different drug release behavior as well as having an
optimal composition for printability. Three different ibuprofen
attached reactive prodrugs were synthesized through an esterifi-
cation reaction to produce IJ3DP printed tablets (or implants; in
the context of this paper these terms are interchangeable with
the rate of drug release required, being the only major differ-
ence). Controlled release was achieved by mixing the synthe-
sized reactive prodrug with different mole ratios of hydrophilic
co-monomers. During printing and exposure to UV radiation,
these formulations produced co-polymerized products with dif-
ferent hydrophilicity, and thus different release rates.
Preliminary printability of all the formulations was screened
by assessing their miscibility, viscosity, and printability (Table S1,
Supporting Information). The ink formulations with physical
properties recognized as indicating they could be jetted were
placed into a Dimatix 10 pL Cartridge ready for tablet produc-
tion. All the samples were printed onto a coverslip and exposed
to a UV dose after each swathe of ink deposition. Inks for IJ3DP
process were chosen for those having reliable droplet formation
and able to cure within a short period of UV exposure in order
that the droplets pin to the deposited location and able to support
any subsequent ink layers placed upon it during the formation of
3D structures.
To minimize oxygen inhibition,[39,40] printing was conducted
under a nitrogen-rich environment where the oxygen level was
0.25% ± 0.05%. Different ink formulations showed very dissim-
ilar solidification performance during the printing process. The
hydroxyethyl methacrylate (IBHEMA) prodrug monomer mixed
with hydroxyethylmethacrylate (HEMA) showed some solid frag-
ments, but no uniform film was achieved. By replacing HEMA
with hydroxyethyl acrylate (HEA), increased solidificationwas ob-
served after the printing and curing process. However, still no
well-defined filmwas observed (Figure S1a, Supporting Informa-
tion). This trend in the solidification performance matches the
general observation that free radical polymerization propagation
kinetics are higher with acrylate monomers when compared to
methacrylates that contain similar pendant groups.[41,42] Finally,
the ink formulation was further improved by replacing IBHEMA
with ibuprofen attached hydroxyethyl acrylate (IBHEA), such that
an acrylate-based reactive linker was used. The IBHEA-HEA for-
mulations showed sufficient curability to form a defined solid
structure through IJ3DP (Figure S1a, Supporting Information).
In order to test how printedmaterials performed under a range
of physiologically relevant conditions, drug release was studied
in phosphate-buffered saline (PBS) media under a range of pH
covering acidic, neutral, and alkaline environments. The printed
samples were placed into different media, during which the drug
released into the media after the ester bonds were hydrolyzed.
The hydrophilicity of the polymerized molecules was tuned by
varying the amount of the HEA monomer (HEA is hydrophilic
due to the pendant hydroxyl group, and thus both HEA and
poly-HEA are water soluble).[43,44] Conversely, the attachment of
ibuprofen on to HEA consumes the hydroxyl and converts it
into an ester bond. Thus, the esterification process makes both
the ibuprofen (loss of carboxylic acid) and HEA (hydroxyl loss)
more hydrophobic.[45,46] Consequently, the synthesized IBHEA
acts as a hydrophobic component in the final two component
formulations and so varying the ratio of the hydrophobic IB-
HEA and hydrophilic HEA allows the overall hydrophilicity of
the co-polymerized final specimens to be tuned. This, in turn, al-
lows control of the rate of hydrolysis and therefore drug release
(Figure 2a).
Specimens were manufactured by IJ3DP and the release ex-
periment was carried out in a PBS media under pH 2, 7, and 12
inside an incubator maintained at 37 °C. The ibuprofen release
was measured over 20 days (Figure 2b).
Figure 2b shows that under all pH environments, the spec-
imens that contain higher concentrations of HEA exhibited
faster ibuprofen release, suggesting that the HEA allowed for
greater intimate contact between the ester bonds and the wa-
ter molecules that drive hydrolysis. In an alkaline environment,
the release was considerably increased, indicating a base cat-
alyzed release mechanism. For example, after 120 h, the speci-
mens were printed using a formulation that contained 30 mol%
of IBHEA, released 87.6 wt% of the loaded ibuprofen in a pH 12
environment, while the specimens in pH 2 and pH 7 released
20.1 wt% and 21.2 wt%, respectively. Furthermore, in an alka-
line environment, the release rate was more sensitive to the over-
all hydrophilicity (or loading) of the final molecule; for example,
when the IBHEA loading reached 70mol%, release went down to
0.68 wt% after 120 h while in pH 2 and pH 5, the release reached
around 3 wt%.
It was found that the release under alkaline conditions was
similar to zero order. This suggested that during the test period,
the drug was released at a constant rate despite the residual drug
concentration. However, by comparing the release profile of the
three formulations at pH 12, we see that the release behavior
falls into the linear region of Higuchi drug release kinetics. At
pH 7 and 2, the release profile fits to a Korsmeyer–Peppas model
(R2 > 0.98) with an n value between 0.38 and 0.50, implying that
the release behavior is close to quasi-Fickian diffusion. At pH
12, the drug release study of tablets with 70 mol% and 50 mol%
of IBHEA were halted at 120 h and 216 h, respectively. Beyond
these times the tablets had disintegrated (Figure 2c): during dis-
solution, the poly-IBHEA-HEA copolymer decomposes to poly-
HEA homopolymer (Figure 2c), a water-soluble polymer. Conse-
quently, beyond these time points it was not possible to replace
media for the following time point as removing media also re-
moves polymer debris from then on.
Through the IJ3DP process, the geometry and design of the
drug delivery device can all be manipulated, providing a further
level of control over the release rate of the drug from the device.
As a proof of concept, two mesh structures with the same over-
all dimensions (10 mm×10 mm) but different mesh hole sizes
were printed and tested over 5 days at pH 12. The result in Fig-
ure 3a shows that mesh A (2 mm feature size) which had 7.3%
more surface/volume ratio than mesh B (1.2 mm feature size)
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Figure 2. a) Tuning the hydrophilicity of the final polymer chain has a direct impact on the hydrolysis rate for the temporary linkage and therefore
influences the drug release rate; b) The printed structure shows different release behaviors in different pH environments, but overall, themore hydrophilic
molecules display a faster release speed (mean ± SD, n = 3); c) The pictures on the left from top to bottom show the change of the physical state of the
specimens after the specified percentage of drug release. The whole device becomes soluble in water and can be washed away after delivery is complete.
A schematic of the molecular state is shown on the right.
Figure 3. Through multi-material IJ3DP process, a complex drug delivery device was achieved. a) Devices with different geometries and construction
were printed and tested under pH 12 within 5 days and the results demonstrated the capability of tuning the drug releasing rate by structural design
(mean± SD, n= 3). b) An exemplar of a complex drug delivery device that can be achieved by using IJ3DP, a University of Nottingham logo with 70mol%
of ibuprofen loading was embedded in a tablet; c) Tof-SIMS characterization of a printed 50–50 mol% (IBHEA-HEA) tablet, where the drug molecules
were observed to be homogeneously distributed.
exhibited about 10.2% faster releasing speed. A more complex
multi-material core shell structure was also printed, in which the
same drug loaded ink formulation (30 mol% ibuprofen loading)
was embedded into an inkjet printed poly-HEA (0 mol% ibupro-
fen loading) shell by co-printing both formulations. It showed
that the release of ibuprofen was significantly slowed when us-
ing a core shell structure. Such a system could therefore enable
“programming” of the drug release behavior at the voxel level
(typically of the order of 50 𝜇m) by using a multi-material 3D
inkjet printing process, in which the ratio of the two monomers
can be controlled spatially to print a 3D device that has different
release behavior in different regions of the object. Figure 3b is a
concept device produced by IJ3DP showing that with the multi-
material capability and exceptional voxel resolution, a more com-
plex tablet design is possible and therefore enables the potential
for “dialed up” release profiles.
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To assess the chemical state of the ibuprofen before and after
the printing process, Fourier transform infrared spectroscopy
(FTIR), Proton nuclear magnetic resonance (H’NMR), and
Time-of-flight secondary ion mass spectrometry (ToF-SIMS)
analyses were carried out. The FTIR and H’NMR showed
that the ibuprofen molecule has been successfully attached to
the carrier and was stable after being formulated into inkjet
printable formulations (Figures S2 and S3, Supporting Informa-
tion). The printed samples were examined confirming that the
ibuprofen molecules were not degraded or detached from the
polymer carrier after the IJ3DP process (Figure S6, Supporting
Information). Tof-SIMS (with depth analysis) was introduced to
further investigate the state of the ibuprofen drug, in which no
chemical or physical changes were observed to the loaded drug
molecules through the inkjet print process. Two secondary ions
from the Tof-SIMS spectra that are characteristic of the drug cova-
lent linkage: [M-H]OCH2CH2
+ and [M-COOH]+, where M is the
ibuprofenmolecule (C13H18O2), were used tomap 3D spatial dis-
tribution of the covalently-linked drug (Figure 3c, left) and further
data were provided in Figure S4, Supporting Information. No
ibuprofen precipitation or recrystallization was observed within
the analyzed volume apart from the first few nanometers at the
surface where island-like features were observed. Such island
formation was only observed at the very top surface and shows an
intense secondary ion yield only for fragments that are typical of
linear, saturated polymers (such as the fragment C5H9
+) of which
3D distribution is also shown in Figure 3c, right. Therefore,
the likely explanation is that minute amounts of low molecular
poly-HEA migrate to the surface during the printing process.
Unreacted acrylate monomers are normally not compatible
with cells and often pose a risk during therapeutic use. There-
fore, the level of residual acrylate group in the final tablets was
examined to assess this potential risk. Fourier transform infrared
spectroscopy-attenuated total reflection (FTIR-ATR) was used to
assess presence of unreacted acrylate groups on the sample sur-
face. For comparison, the uncured ink formulation and inkjet
printed tablets were analyzed and compared (Figure S5, Support-
ing Information). Unreacted acrylate groups contain characteris-
tic peaks at 1636 cm−1 (acrylate C═C stretches) and 810 cm−1
(═CH2 twisting).
[23] It was found that all the characteristic peaks
related to unreacted acrylates disappeared in the final product
indicating high conversion. As FTIR-ATR is a surface-based tech-
nique (≈tens ofmicrons), in order to further track unreacted acry-
lates through the whole sample, specimens from each formu-
lation were dissolved and characterized by H’NMR (Figure S6,
Supporting Information). As no characteristic peak for the acry-
late groups in either HEA or IBHEA were observed, it was fur-
ther confirmed that the printed sample achieved high conversion.
A cytotoxicity test (following ISO 10 993) was also carried out
with all the inkjet printed specimens where no cytotoxicity was
observed on mammalian BJ6 cells over thirty days (Figure S7,
Supporting Information). The molar mass of the sample was cal-
culated usingMALLS (MWMALLS). The number averagemolecular
weight of the inkjet printed samples reached 5900–9200 g mol−1
and the weight average molecular weights were between 90 300
and 118 200 g mol−1 (Table S4, Supporting Information).
As the proportion of IBHEA increased, the distribution of
the molecular weight tends to become broader (Figure S8,
Supporting Information).
3. Conclusion
In conclusion, this work has demonstrated that through a strat-
egy of creating a reactive prodrug-based formulation, it is pos-
sible to create a range of drug releasing inks that can be used
with 3DIJP to produce structures with extended drug loading
and controlled release. The loaded drug was shown to be homo-
geneously distributed throughout both the ink formulation and
the printed product without recrystallization or precipitation, in-
dicating physical stability. It was possible to modify the release
rate by a number of means; we showed that we could control
the release via choice of molecules forming the chain and linker,
through variation of the geometry, and through spatially varying
the composition of the tablet. The drug-attached molecule chain
dissolves completely in an aqueous environment when the drug
was fully released and therefore if this approach was to be used
for implants the printed device would not need to be removed.
Such a formulation system, which is readily adaptable to different
small molecular weight drugs, provides a brand new formulation
strategy for IJ3DP. Together with the multi-material printing ca-
pability for IJ3DP, we propose an important step in enabling the
design and production of personalizedmulti-functionalized drug
delivery dosage forms and devices with “programmed” drug load-
ing and release.
Supporting Information
Supporting Information is available from the Wiley Online Library or from
the author.
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